Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022

Brandon G. Truax
doi: https://doi.org/10.1101/2024.04.23.24306221

Article usage

Article usage: April 2024 to June 2025

AbstractFullPdf
Apr 20241981041
May 2024771046
Jun 202441832
Jul 202432124
Aug 20241729
Sep 2024352427
Oct 20242067
Nov 20241437
Dec 202411313
Jan 202525820
Feb 202514168
Mar 202513288
Apr 202526620
May 2025271016
Jun 2025314
Back to top
Posted April 23, 2024.
Download PDF
Data/Code
Email
Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022
Brandon G. Truax
medRxiv 2024.04.23.24306221; doi: https://doi.org/10.1101/2024.04.23.24306221
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area